Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 4 · Randomised trials: 2 · 1947–2026
Showing the 50 most relevant studies, sorted by most relevant.
Toma CC, Marrelli M, Puticiu M, et al.
2024
Arnica L. genus (Asteraceae) comprises perennial herbs native to the temperate and boreal parts of the northern hemisphere. Arnica montana is the main species. It shows different biological activities, such as antioxidant, anti-inflammatory, antibacterial, antifungal, and antitumor effects. The Arnica formulations are mainly used for pain management. This systematic review is aimed at summarizing the studies focusing on the use of Arnica products on pain and inflammatory signs due to traumatic injuries related to sport and surgical interventions as well as to arthritis and other inflammatory conditions. Both phytotherapeutic and homeopathic formulations are taken into account. This paper only includes manuscripts published in mainstream journals. A literature search from Scopus, Web of Science, and PubMed databases has been carried out using a combination of the keywords "Arnica", "trauma", "sport", "injury", "injuries", and "pain". According to the search strategy and inclusion criteria for this study, 42 eligible papers, focusing on both Arnica alone and formulations containing a mixture of plant extracts, have been finally selected. This review critically discusses the in vitro, in vivo, and clinical studies dealing with Arnica products, reporting both positive and negative outcomes, thus providing perspectives for future research on the plant pharmacological potential.
Abstract licence: CC BY
Mathie RT, Clausen J
2015
- Homeopathy
- Veterinary Medicine
- Research
BackgroundNo systematic review has previously been carried out on randomised controlled trials (RCTs) of veterinary homeopathy in which the control group was an intervention other than placebo (OTP). For eligible peer-reviewed RCTs, the objectives of this study were to assess the risk of bias (RoB) and to quantify the effect size of homeopathic intervention compared with an active comparator or with no treatment.MethodsOur systematic review approach complied fully with the PRISMA 2009 Checklist. Cochrane methods were applied to assess RoB and to derive effect size using standard meta-analysis methods. Based on a thorough and systematic literature search, the following key attributes of the published research were distinguished: individualised homeopathy (n = 1 RCT)/non-individualised homeopathy (n = 19); treatment (n = 14)/prophylaxis (n = 6); active controls (n = 18)/untreated controls (n = 2). The trials were highly diverse, representing 12 different medical conditions in 6 different species.ResultsNo trial had sufficiently low RoB to be judged as reliable evidence: 16 of the 20 RCTs had high RoB; the remaining four had uncertain RoB in several domains of assessment. For three trials with uncertain RoB and without overt vested interest, it was inconclusive whether homeopathy combined with conventional intervention was more or was less effective than conventional intervention alone for modulation of immune response in calves, or in the prophylaxis of cattle tick or of diarrhoea in piglets.ConclusionDue to the poor reliability of their data, OTP-controlled trials do not currently provide useful insight into the effectiveness of homeopathy in animals.
Abstract licence: CC BY
Chintamani Nayak, Nivedita Pattanaik, A. Chattopadhyay, et al.
Journal of Complementary and Integrative Medicine, 2020
- Hyperuricemia
- Materia Medica
- Uric Acid
Keller D, Sundrum A
2018
- Cattle
- Mastitis, Bovine
- Anti-Bacterial Agents
Based on the widespread use of homeopathy in dairy farm practice when treating mastitis, a blind randomised controlled trial (RCT) was conducted to assess the effectiveness of homeopathic treatment of clinical mastitis on four dairy farms. The study considered specific guidelines for RCTs as well as the basic principles of individualised homeopathy and involved 180 lactating dairy cows. Evaluation of cure rates was based on clinical investigation of the udder and on laboratory analysis of milk samples. In culture-positive cases, the antibiotic treatment provided suboptimal bacteriological cures (60-81 per cent) but was more effective than individualised homeopathy (33-43 per cent) whose effects appeared little different to those of placebos (45-47 per cent) (P≤0.05). On the cytological cure level, all three treatment methods were similarly ineffective: antibiotic being 2-21 per cent, individualised homeopathy 0-8 per cent and placebo 3-13 per cent (P≤0.05; P=0.13). Antibiotics, individualised homeopathy and placebo had similar effects on bacteriological and cytological cure in cases of culture-negative milk samples (P>0.4) and Escherichia coli infections (P=1.0). The study results implied that the effectiveness of individualised homeopathy does not go beyond a placebo effect and successful treatment is highly dependent on the specific mastitis pathogen. Thus, antimicrobial or alternative remedies used should be based on the bacterial culture of the milk sample.Trial registration numberNTP-ID: 00008011-1-9, Pre-results.
Abstract licence: CC BY-NC
2024
Massara Mzid, S. Ben Khedir, Maryem Ben Salem, et al.
Pharmaceutical Biology, 2017
Abstract Context: Urtica urens L. (Urticaceae) is an important and commonly used plant for its medicinal and pharmacological properties. Objective: We analyzed the antioxidant and antimicrobial activities of the leaves of Urtica urens in ethanol (EtOH) and water (WA) solvents, employing standard analytical methods. Materials and methods: Polyphenol, flavonoid and tannin content of Urtica urens leaves were determined, after their extraction, using EtOH (70%) and WA extracts as well as the antioxidant (DPPH, ABTS, β-carotene and FRAP) and the antibacterial (via the method of dilution tests) activities of EtOH and WA extracts. Results: The 70% EtOH of Urtica urens showed the highest values of total phenolic (31.41 mg GAE/g DW), flavonoids (6.81 mg quercetin/g DW), tannin (8.29 mg GAE/g DW) and TEAC (560 mmol Trolox/g DW), compared to the WA. The results of DPPH for EtOH (95.56%) were higher than that of WA (64.56%) at a concentration of 40 mg/L. The extracts displayed a FRAP 106.23 for EtOH and 30.55 μmol Fe(II)/g DW for WA. The results clearly indicated that EtOH was the strongest radical scavenger (IC50 = 245.65 ± 10.2 μg/mL). Ethanol was the most effective with minimum inhibitory concentration (MIC) < 250 μg/mL. WA has no antibacterial activity. Discussion and conclusion: The results indicate that leaves of Urtica urens could be used as natural antioxidant and antimicrobial agents.
Abstract licence: CC BY 4.0
N. Emmelin, W. Feldberg
The Journal of Physiology, 1947
Yevheniia ZALYHINA
Fitoterapia, 2022
Doukkali Zouhra, Meryem El Jemli, A. Bouyahya, et al.
Progress In Microbes & Molecular Biology, 2023
Important Moroccan medicinal plants known for their food and medicinal potential include Urtica urens and Mercurialis annua. We examined the antioxidant activity of the methanolic and aqueous extracts by several in vitro systems of the assay, namely the ferric reducing/antioxidant power (FRAP) assay, the DPPH radical-scavenging activity, and the ABTS free radical-scavenging capacity. In addition, all active extracts were subjected to phytochemical screening to determine the key groups of chemicals implicated in their therapeutic activity. Total phenolic and flavonoid concentrations were also measured to see how they affected the antioxidant properties of the plant extracts. The extracts of Urtica urens and Mercurialis annua were found to have different levels of antioxidant effect in the systems tested. Based on the three different antioxidant assays, the Mercurialis annua extracts showed the highest values of antioxidant ability, based on the three used assays. Phytochemical testing of studied extracts revealed the presence of flavonoids, anthocyanins, and tannins. Total phenol and flavonoid contents were shown to provide the highest association with different antioxidant methods. The present study provides evidence that the extracts of Urtica urens and Mercurialis annua are a potential source of natural antioxidants, and this justifies their uses in Moroccan traditional medicine.
Abstract licence: CC BY-NC 4.0
Ali Khakpour, Negar Ahmadi Shadmehri, Hanif Amrulloh, et al.
Bioactivities, 2023
Various agricultural products are known to have anti-microbial, anti-cancer, and anti-inflammatory effects. As we can mention, Walnut (Juglans regia) husk, orange (Citrus sinensis) peel, Broad bean (Vicia faba) peel, and Nettle (Urtica urens) are proven to have antimicrobial and anticancer actions. Also, plant diseases such a Pectobacterium carotovorum, Ralstonia solanacearum, Dickeya chrysanthemi, and Pseudomonoas syringae are known to cause annual damage to plant products. Therefore, in the current study, the researchers evaluated their antibacterial activity on the mentioned bacteria under in vitro conditions. Extracts of J. regia husk, C. sinensis peel, V. faba outer peel and U. urens were prepared by maceration method and their anti-bacterial activity on P. carotovorum, D. chrysanthemi, P. syringae, R. solancearum was evaluated using blank disk and well diffusion to obtain minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) values. J. regia (husk) and V. faba (outer peel) extracts revealed an anti-bacterial effect on all 4 studied bacteria, while C. sinensis (peel) only inhibited the growth of P. syringae and U. urens only had this effect on P. syringae and R. Solancearum. The inhibition zones varied from 8 to 14 mm, while almost all MIC and MBC rates were 6.25 and 12.5 mg/mL, respectively. Based on the antimicrobial results, the extracts that showed suitable antibacterial effects on certain bacteria can be further studied to be used as natural pesticides.
Abstract licence: CC BY 4.0
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.